tWith ties to Duke University, DxTerity Diagnostics, Inc. is a molecular diagnostics company, providing genomic testing solutions. The company's primary product is REDI-Dx RUO test, a molecular test for acute radiation exposure based on its DxTerity DxDirect method for direct-from-sample, multiplex gene-expression analysis; and DxCollect, a sample collection product line that stabilizes whole blood samples for transport and storage applications. The firm's novel gene expression platform enables gene expression analysis without RNA isolation. The company also has DxDIRECT Probes, DxTerity Reagent Kits, in addition to DxCollect. In 2011, DxTerity bought from fellow SBIR Awardee SourceMDx which ceased business operations that year, the IP rights (including patents) for three blood-based cancer diagnostics
